Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

237 Citaten (Scopus)

Samenvatting

The cumulative incidence of anthracycline-induced clinical heart failure (A-CHF) in a large cohort of 830 children treated with a mean cumulative anthracycline dose of 288 mg/m2 (median 280 mg/m2; range 15-900 mg/m2) with a very long and complete follow-up after the start of anthracycline therapy (mean 8.5 years; median 7.1 years; range 0.01-28.4 years) was 2.5%. A cumulative anthracycline dose of 300 mg/m2 or more was the only independent risk factor (relative risk (RR) = 8). The estimated risk of A-CHF increased with time to 5.5% at 20 years after the start of anthracycline therapy; 9.8% if treated with 300 mg/m2 or more. In conclusion, 1 in every 10 children treated with a cumulative anthracycline dose of 300 mg/m2 or more will eventually develop A-CHF. This is an extremely high risk and it reinforces the need of re-evaluating the cumulative anthracycline dose used in different treatment protocols and to define strategies to prevent A-CHF which could be implemented in treatment protocols.

Originele taal-2Engels
Pagina's (van-tot)3191-3198
Aantal pagina's8
TijdschriftEuropean Journal of Cancer
Volume42
Nummer van het tijdschrift18
DOI's
StatusGepubliceerd - dec. 2006
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study'. Samen vormen ze een unieke vingerafdruk.

Citeer dit